PDF(Pubmed)
Abstract：
Unfortunately, ovarian cancer is still diagnosed most often only in an advanced stage and is also the most lethal gynecological cancer. Another problem is the fact that treated patients have a high risk of disease recurrence. Moreover, ovarian cancer is very diverse in terms of molecular, histological features and mutations. Many patients may also develop platinum resistance, resulting in poor response to subsequent lines of treatment. To improve the prognosis of patients with ovarian cancer, it is expected to make better existing and implement new, promising treatment methods. Targeted therapies seem very promising. Currently, bevacizumab - a VEGF inhibitor and therapy with olaparib - a polyADP-ribose polymerase inhibitor are approved. Other methods worth considering in the future include: folate receptor α, immune checkpoints or other immunotherapy methods. To improve the treatment of ovarian cancer, it is also important to ameliorate the determination of molecular features to describe and understand which group of patients will benefit most from a given treatment method. This is important because a larger group of patients treated for ovarian cancer can have a greater chance of surviving longer without recurrence.
摘要：
不幸的是,卵巢癌通常仅在晚期才被诊断，也是最致命的妇科癌症。另一个问题是接受治疗的患者具有很高的疾病复发风险。此外，卵巢癌在分子方面非常多样化，组织学特征和突变。许多患者也可能出现铂类耐药，导致对后续治疗的反应不佳。改善卵巢癌患者的预后,预计将更好地现有并实施新的，有希望的治疗方法。靶向治疗似乎非常有希望。目前,贝伐单抗-一种VEGF抑制剂和奥拉帕尼-一种聚ADP-核糖聚合酶抑制剂的治疗被批准。未来值得考虑的其他方法包括：叶酸受体α，免疫检查点或其他免疫疗法。提高卵巢癌的治疗水平，改善分子特征的测定也很重要，以描述和了解哪一组患者将从给定的治疗方法中受益最大。这很重要，因为接受卵巢癌治疗的患者中有更大的机会存活更长时间而不复发。
